Carolyn D. Runowicz, M.D.
- Executive Associate Dean for Academic Affairs, Professor of Obstetrics and Gynecology
- AHC2 672
Dr. Runowicz is a nationally and internationally recognized leader in women's health and gynecologic cancer. Her research has focused on the development, initiation and conduct of clinical trials in gynecologic cancer and in cancer prevention. She has authored more than 200 scientific articles.
She has received numerous honors and awards, including the University of Connecticut Distinguished Alumni Award, the American Medical Women's Association Local Legend Award, Cancer Care Physician of the Year Award, and the American Society of Clinical Oncology Statesman Award.
She has served in leadership roles in the major cancer organizations. She served as the first woman president of the Society of Gynecologic Oncologists (2000), was President of the American Cancer Society (2005) and served on the National Cancer Advisory Board (NCAB), appointed by President George W. Bush. She served as Chair of the NCAB for 4 years (2006-2010). She is currently serving on the Board of Directors of the American Society of Clinical Oncology (2011-2015) and as Vice President of the American Gynecological and Obstetrical Foundation Board.
She has served on numerous committees for the Society of Gynecologic Oncologists, American College of Obstetricians and Gynecologists, American Cancer Society, the National Cancer Institute, the National Surgical Adjuvant Breast and Bowel Project, the American Society of Clinical Oncology and the American Gynecologic and Obstetrical Society.
She is a reviewer for medical journals and serves on several editorial boards in recognition of her expertise in women's health and gynecologic cancers. She is on several scientific advisory boards, including the National Cancer Institute and the Ovarian Cancer Research Foundation
Selected recent publications:
1. Goldstein SR, Neven P, Cummings S, Colgan T, Runowicz CD, Krpan D, Proulx J, Johnson M, Thompson D, Thompson
J, Sriram U. Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial: 5-year gynecological
outcomes. Menopause 18: 17-22, 2011
2. Baer AR, Kelly CA, Bruinooge SS, Runowicz CD, Blayney DW. Challenges to National Cancer Institute-Supported
Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. J Oncol Pract 6: 114-7,
3. Swede H, Gregorio DI, Tannenbaum SH, Brockmeyer JA, Ambrosone C, Wilson LL, Pensa MA,Gonsalves L, Stevens
RG, Runowicz CD. Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study. Clin
Breast Cancer 11: 332-41, 2011
4. Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N.
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene
(STAR). Am J Obstet Gynecol, 2011 (Epub ahead of print)
5. Starbuck K, Garcia C, Wu Q, Runowicz CD. Multimodal therapy in the treatment of vaginal adenocarcinoma arising
from endocervicosis. Gynecol Oncol 120: 158-9, 2011
6. Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ,
Boccia RV, Runowicz CD, Rose PG. Randomized phase III study of canfosfamide in combination with pegylated
liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer 20: 772-80, 2010
7. Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, et al. Erlotinib added to carboplatin and paclitaxel as firstline
treatment of ovarian cancer: a phase II study based on surgical reassment. Gynecol Oncol 119: 451-6, 2010
8. Baer AR, Kelly CA, Bruinooge SS, Runowicz CD, Blayney DW, Challenges to National Cancer Institute-Supported
Cooperative Group Clinical Trials Participation: An ASCO Survey of Cooperative Group Sites. J Oncology Pract 6: 114-
9. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon
ER, Wade Jl 3rd, Robidoux A, Margolese RG, James J, Runowicz CD et al. Update of the National Surgical Adjuvant
Breast and Bowel Project Study of Tamoxifen and Raloxifened (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev
Res 3:epub, 2010
10. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy opportunities, progresses
and challenges. J Hematol Oncol 10: 3-7, 2010
11. Khalil I, Brewer, MA, Neyarapally T, Runowicz CD. The potential of biologic network models in understanding the
etiopathogenesis of ovarian cancer. Gynecol Oncol 116: 282-5, 2010